Cite
Thompson JC, Carpenter EL, Silva BA, et al. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. JCO Precis Oncol. 2021;5doi: 10.1200/PO.20.00321.
Thompson, J. C., Carpenter, E. L., Silva, B. A., Rosenstein, J., Chien, A. L., Quinn, K., Espenschied, C. R., Mak, A., Kiedrowski, L. A., Lefterova, M., Nagy, R. J., Katz, S. I., Yee, S. S., Black, T. A., Singh, A. P., Ciunci, C. A., Bauml, J. M., Cohen, R. B., Langer, C. J., & Aggarwal, C. (2021). Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. JCO precision oncology, 5. https://doi.org/10.1200/PO.20.00321
Thompson, Jeffrey C, et al. "Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy." JCO precision oncology vol. 5 (2021). doi: https://doi.org/10.1200/PO.20.00321
Thompson JC, Carpenter EL, Silva BA, Rosenstein J, Chien AL, Quinn K, Espenschied CR, Mak A, Kiedrowski LA, Lefterova M, Nagy RJ, Katz SI, Yee SS, Black TA, Singh AP, Ciunci CA, Bauml JM, Cohen RB, Langer CJ, Aggarwal C. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. JCO Precis Oncol. 2021 Mar 19;5. doi: 10.1200/PO.20.00321. eCollection 2021. PMID: 34095713; PMCID: PMC8169078.
Copy
Download .nbib